Jpmorgan Chase & CO Regenxbio Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RGNX
# of Institutions
182Shares Held
45.4MCall Options Held
64.9KPut Options Held
103K-
Black Rock Inc. New York, NY8.61MShares$73.5 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.79MShares$40.9 Million3.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$29.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.07MShares$17.7 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.4MShares$11.9 Million0.02% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $369M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...